Insider Selling: Insmed Incorporated (NASDAQ:INSM) CFO Sells $227,979.00 in Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 3,470 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total value of $227,979.00. Following the completion of the sale, the chief financial officer now directly owns 114,736 shares in the company, valued at $7,538,155.20. This represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52.

Insmed Stock Down 0.7 %

Shares of NASDAQ:INSM opened at $65.25 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market cap of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The firm has a fifty day moving average price of $71.23 and a 200 day moving average price of $72.46.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The business’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same period last year, the business earned ($1.10) EPS. Sell-side analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Analyst Ratings Changes

INSM has been the topic of a number of analyst reports. Truist Financial restated a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Finally, Bank of America raised their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Insmed has an average rating of “Moderate Buy” and an average target price of $83.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of INSM. Geode Capital Management LLC raised its stake in shares of Insmed by 4.7% during the third quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock worth $278,432,000 after purchasing an additional 172,664 shares during the last quarter. Darwin Global Management Ltd. purchased a new position in Insmed during the 2nd quarter worth $237,076,000. Principal Financial Group Inc. raised its position in Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after buying an additional 214,130 shares during the last quarter. Clearbridge Investments LLC lifted its stake in shares of Insmed by 76.8% in the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after acquiring an additional 714,539 shares during the period. Finally, Vestal Point Capital LP boosted its holdings in shares of Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.